Compare Duolingo Inc (DUOL) vs Tango Therapeutics Inc. (TNGX) Price & Performance

Duolingo (DUOL) trades at $139.73, down 5.42% on the day, as the stock consolidates near key technical support levels. The company demonstrates strong fundamental performance with 2025 revenue reaching $1.04 billion and net income of $414 million, representing a robust 39.9% profit margin. Recent earnings beats and analyst consensus of $142.50 price target suggest underlying strength despite recent price weakness. Technical indicators show a bullish moving average signal with neutral oscillators, while institutional sentiment remains mixed with notable insider selling activity.

Duolingo presents a compelling growth story with exceptional profitability metrics and consistent earnings outperformance. The primary investment opportunity lies in the company's AI-driven platform expansion and strong user growth momentum. Key risks include CEO share liquidations, competitive pressures in edtech, and valuation concerns at current levels. The stock's current discount to consensus target offers potential upside if execution continues.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.